Tanja Obradovic’s Post

It’s time to find out who bagged the biggest private biotech investments in June 2024! 💰 The biggest funding rounds went to the companies Formation Bio, ITM Isotope Technologies Munich SE, and Marea Therapeutics. 📈 Meanwhile, around the world, oncology and central nervous system players attracted the biggest funding rounds overall. 🌍 Read our latest article to find out more about biotech’s biggest private investments in June, as we break down the investments by location and funding type, and compare June’s fundraising to previous months. 💡 https://lnkd.in/dYvuBVt9 #biotechinvestments #oncologyresearch #biotechfunding #healthcareinnovation #investmenttrends #globalbiotech #lifesciences Santa Ana Bio, Inc. | Alzheon, Inc. | Preserving Future Memories | Bright Peak Therapeutics | iOnctura | InduPro | Exsilio Therapeutics | Elion Therapeutics | Enveda Biosciences | Iambic Therapeutics | Spur Therapeutics | āshibio, Inc | Adcytherix | Envisagenics | Vilya | Frontier Medicines | Augustine Therapeutics | GPN Vaccines

🚀🔬 It’s time to take a look at the biggest private biotech investments of July 2024! 💰 Last month, the companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest investment rounds. 🎯 And, just as in June, oncology and central nervous system players attracted the biggest funding rounds overall. 🧠💉 📍Plus, in terms of location, North America and Europe also achieved the same amount of fundraising rounds as they did in June, with 15 and 11 respectively. 🌍💼 Read our latest article to find out more details! 🔍 https://lnkd.in/d4xze2x7 #biotech #investments #pharma #oncology #innovation #funding #biotech2024 #healthcare CatalYm GmbH | Scorpion Therapeutics | NGM Biopharmaceuticals | Myricx Bio | Asceneuron SA | Autobahn Therapeutics, Inc. | SciRhom | Confo Therapeutics | GRO Biosciences | AIRNA | SmartCella Holding AB | AusperBio | Rona Therapeutics | CellCentric | ReviR Therapeutics | LTZ Therapeutics

Stories making headlines today in the biopharma industry: Biotech companies, focusing on radiopharmaceuticals, neuroscience, and inflammation therapies, are being acquired for substantial premiums due to their potential to bridge gaps in the pharmaceutical field. For instance, Bristol Myers Squibb purchased radiopharmaceutical company RayzeBio at a 104% premium just three months post-IPO. Raising the bar in the oncology biotech space, Pennsylvania-based ArriVent BioPharma prepares for a $175 million IPO on Nasdaq with its furmonertinib, an EGFR-targeted tyrosine kinase inhibitor, being its lead asset. Venture capital player Innovation Endeavors, co-founded by ex-Google CEO Eric Schmidt, has launched a new $630 million fund. A significant portion of this fund will invest in life sciences and healthcare, indicating the firm's increasing focus on biotech. Merck's cancer prevention drug, Keytruda, demonstrates a 31% reduction in the risk of bladder cancer recurrence or death post-surgery. Despite not achieving its expected survival endpoint, the interim analysis data shows promise. In other news, Deerfield exits a 2017 deal with Windtree Therapeutics, while Travere Therapeutics finalizes a new $120 million deal with Renalys Pharma. Additionally, Celularity raised $21 million, and Sagimet Biosciences plans for a $112.5 million public offering. Moving towards pipeline development, Strand Therapeutics scales back its workforce by 18%. However, stay optimistic as CEO Jacob Becraft assures the firm’s robust financial runway. Navigating through challenges in 2023, Lonza remains hopeful about revenue growth this year along with plans to shutter its second biologics site soon. Personal updates reveal Bayer's radiology head planning retirement and ex-Sanofi chief Olivier Brandicourt joining BeiGene’s board. After facing a dip in VC and financing in 2023, the UK's life sciences sector now seems primed for an upward trajectory. #pharma #biotech #topstories #biodatastudio

Wow! Recursion Pharmaceuticals has agreed to buy Exscientia for $688 million in an all-stock deal, merging two leading AI-driven drug discovery platforms. This acquisition enhances Recursion's pipeline and partnerships, gaining assets from Exscientia, known for collaborations with Sanofi and Merck. The combined entity will have nearly $850 million in cash to advance treatments for rare diseases and cancer. Recursion aims to "make medicines better and faster" by leveraging Exscientia's AI drug discovery capabilities. This deal underscores AI's transformative role in revolutionizing the traditionally slow drug development process. I believe this powerful merger will yield exciting innovations in the coming years. https://lnkd.in/eUwRtnPn #Biotech #AI #DrugDiscovery #Innovation #Healthcare #Recursion #Exscientia

Biotech/Pharma Industry Update Time 👨🔬 🚨 👩🔬 Below are some exciting updates which have taken place within the Biotech/Pharma industry over the last week 💥💥💥 🍾 - Totus Medicines have successfully closed a $66 Million Series B funding & also have named Nassim Usman as their new CEO. ✅ 🍾 - Rain Oncology have announced it has entered into a definitive merger agreement whereby Pathos will acquire them for $1.16 in cash per share plus a non-tradeable contingent value. ✅ 🍾 - Spyre Therapeutics, a biotechnology spinout working on antibody drugs for diseases of the gut, announced Friday a $180 Million fundraising from a group of blue-chip investors.✅ 🍾 - Moderna & Merck Group reported last week that their personalized melanoma cancer vaccine plus Keytruda approach delivered “continued improvement” in reducing risk of disease recurrence or death, based on three-year data from a mid-stage trial.✅ 🍾 - Electra Therapeutics have appointed Kathy Dong as their new CEO, she will replacing current CEO Adam Rosenthal who will still remain the CEO of Star Therapeutics, the company that spun out Electra.✅ 🍾 - Encellin a San Francisco based biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), have successfully closed a $9.9 Million financing round - CEO (Crystal Nyitray).✅ 🍾 - Novo Holdings founded biotech Hoba Therapeutics have raised $25 Million in Series A financing to bankroll its investigational medicines for pain and hearing loss.✅ 🍾 - Vertex Pharmaceuticals have entered a license agreement with Editas Medicine to use the latter company’s Cas9 gene editing technology. Vertex will pay $50 Million upfront, with an additional contingent $50m payment, according to documents filed with the U.S. Securities and Exchange Commission.✅ 🍾 - Immunotherapy biotech EvolveImmune Therapeutics have raised $37 Million in a financing round, backed by big names like Pfizer & its newest investor, Bristol Myers Squibb.✅ #Elixir #IndustryUpdates #Biotechnology #Pharma #News #FDA #Mergers #ClinicalTrials #Approvals #Announcements

Stories making headlines today in the biopharma industry: Gilead is making a strategic move with a $43.5 million investment in Xilio Therapeutics' IL-12 program dedicated to cancer treatment, a deal comprising $30 million in operational cash and $13.5 million stock investment. This venture opens the possibility for Xilio to get up to $604 million from licensing. Meanwhile, Metagenomi remains secretive about its Investigational New Drug (IND) plans. Expected to launch a duo of INDs by 2027, the preclinical IPO sector firm is driven to develop novel enzymes and gene-editing tools that could revolutionize the biotech industry. Aldeyra is also advancing its clinical programs, prepping for another trial for its dry eye disease drug, reproxalap. This comes as part of the firm's NDA resubmission strategy for the year, spurred by the encouraging data from a recent clinical trial. Bayer, the pharmaceutical heavyweight, is trimming its operations, planning for 90 job cuts. Concurrently, Avalo Therapeutics is seeking to boost its financial muscle in a private placement valuing up to $185 million. Changes are not only experienced at the macro level; ADC startup Mythic is experiencing a shift in leadership, set to induct Jazz executive George Eliades as its new leader starting April 1. In the regulatory space, the FDA has endorsed Akebia's anemia drug, vadadustat, a significant bounce-back following a rejection two years prior due to safety qualms. Boundless enters the IPO scene with a bang, generating a $100 million listing for its cancer small molecules. Moderna is also recalibrating its future vaccine strategies in an attempt to amplify the effectiveness. In the funding realm, Intellihealth, a weight loss care provider based in Connecticut, successfully raised $24 million, while Moderna partnered with Blackstone on flu shots securing a robust $750 million in R&D financing. This proves that despite significant challenges, the pharmaceutical and biotechnology sectors continue to adapt, innovate, and expand. #pharma #biotech #topstories #biodatastudio

Merger & Acquisition Life Science / Healthcare 2023 Landscape Review Already this year we’ve seen Sanofi enter an agreement to acquire all outstanding shares of Inhibrx, Inc., as well as Johnson & Johnson’s recent acquisition of Ambrx Biopharma. 🔍 A quick review of Beacon Deals & Companies showed we identified 86 M&A deals last year 🔍 So, here’s one from every month … 🤝December: Bristol Myers Squibb Announced Definitive Merger Agreement to Acquire RayzeBio 🤝November: Selecta Biosciences Announces Merger with Cartesian Therapeutics 🤝October: Kyowa Kirin, Inc.- U.S. to Acquire Orchard Therapeutics 🤝September: Renovaro Biosciences Inc. and GEDiCube Sign Definitive Agreement to Combine 🤝August: Serina Therapeutics, Inc. and AgeX Therapeutics, Inc. Enter into Merger Agreement 🤝July: Biogen to Acquire Reata Pharmaceuticals, Inc. 🤝June: Talaris Therapeutics and Tourmaline Bio Entered into Merger Agreement 🤝May: Pyxis Oncology to Acquire Apexigen 🤝April: NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV 🤝March: Flamingo Therapeutics Signed a Definitive Merger Agreement with Dynacure 🤝February: Kite Pharma Completed the Acquisition of Tmunity Therapeutics Incorporated 🤝January: Leap Therapeutics Acquires Flame Biosciences If you’re interested in learning more about how Beacon tracks the company and deal data in the Cell Therapy, Gene Therapy, RNA, ADC, Bispecific, Immune Tolerance, Checkpoint, Cytokine, DDR, TPD, Microbiome, Cancer Vaccine, or Oncolytic Virus landscapes drop me a message. #drugdevelopment #pharma #MnA #biotech

The companies Jixing Pharmaceuticals, Cour Pharmaceuticals, and OnCusp Therapeutics bagged the biggest private biotech investments in January 2024. Around the world, immunology, oncology, and drug discovery players attracted the biggest funding rounds overall. The first month of 2024 saw a lot of initial public offering (IPO) success stories, suggesting a possible recovery for the biotech industry this year. And, although there was not quite as much private biotech financing in January, with 38 rounds in total, a lot of money was still raised by several companies, with the top three investments of the month coming in at $100 million or more. #biotech #healthcare #londonbiotechshow #healthcareinvestment #londonbusiness

Buy vs R&D: the Pharma version of Open Innovation Pharmaceutical companies look to VC startup portfolios for M&A.   Amgen, Mayo Clinic and AbbVie are set to notch up an exit after fellow investor Merck agreed to buy neurodegenerative disease drug developer Caraway Therapeutics, Inc. for up to $610m, a handy return for a company that had only revealed $23m in funding.  The deal came the same week as Boehringer Ingelheim agreed a $490m purchase of one of its portfolio companies, cancer therapy developer T3 Pharma. As the IPO market continues to stagnate, we might see more deals where pharma firms explore VC and CVC portfolios for acquisitions rather than just backing another funding round. #VC #startup #scaleup #openinnovation #pharma Mind the Bridge

Stories making headlines today in the biopharma industry: BeiGene, the Chinese biotech company, has drawn curtains on its partnership with Shoreline Biosciences which was positioned as BeiGene's step into cell therapy. The collaboration was prematurely terminated, despite a $45 million upfront payment by BeiGene at the outset in January 2022. The partnership was burgeoning to develop cell therapies across four therapeutic targets, with BeiGene tasked with holding worldwide commercial rights. The untimely termination came after a strategic portfolio review, fueled majorly by BeiGene's internal prioritization decisions and not due to flaws in Shoreline’s platform technology. Elsewhere, Gilead Sciences was the sole bidder for liver disease biotech CymaBay Therapeutics, as revealed in recent securities filings. Its initial proposal was amplified by $9.50 per share, eventually settling on a final offer of $32.50 per share, marking a 27% premium to the prior day's closing price. The transaction, worth a mammoth $4.3 billion, underscores a prevailing trend for big Pharma companies to scoop up late-stage deals to consolidate their drug pipelines. Meanwhile, NGM Bio is set to transition to a private company after more than a decade and a half in operation. NGM Bio's largest shareholder, biotech investor The Column Group, is putting plans in motion to privatize the company in a deal estimated at $135.0 million, following a complex R&D journey in NASH, retinal diseases and other areas. In terms of workforce reduction, Thermo Fisher reported a contraction of 8,000 roles, representing about 6% of its workforce in 2023, with the Americas region witnessing the majority of the change. The company noted a 5% dip in its 2023 revenue to $42.86 billion, down from $44.9 billion in the previous year. Finally, Celldex Therapeutics' anti-KIT antibody fulfilled the primary objective in a mid-stage test for chronic spontaneous urticaria, according to initial results. Analysts are optimistic that Celldex's therapy will pose significant competition to a similar but more advanced therapy by Novartis, particularly given there are currently no approved treatments for patients who do not respond to Xolair, a drug manufactured jointly by Novartis and Genentech. #pharma #biotech #topstories #biodatastudio